<DOC>
	<DOCNO>NCT00223925</DOCNO>
	<brief_summary>Cytomegalovirus ( CMV ) infection remain significant problem follow various type transplant associate strong immunosuppressive therapy . Maribavir new oral anti-CMV drug novel mechanism action compare currently available anti-CMV drug . This study test safety anti-CMV activity different dos maribavir give CMV prophylaxis follow stem cell transplant .</brief_summary>
	<brief_title>Maribavir Prevention CMV After Stem Cell Transplants</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>Allogeneic stem cell transplant recipient Recipient CMV seropositive Have transplant engraftment Able swallow tablet CMV organ disease HIV infection Use antiCMV therapy posttransplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Stem cell transplantation</keyword>
	<keyword>Allogeneic transplantation</keyword>
</DOC>